Insider filing
Traded Mar 11 · filed the same day
Derivative exercise or conversion — not an open-market buy.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Traded Feb 12, 2026 · Filed Feb 13, 2026
The CEO of Edwards Lifesciences sold $1.52M of Edwards Lifesciences shares. The filing does not indicate a pre-arranged trading plan.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
open market sale
Code S — open-market or private sale
~$1,524,451
Shares × reported transaction price
2 days after results of Feb 10, 2026, 70 days before results of Apr 23, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $76.44 on Feb 12, 2026, 14% above its 52-week low and 12% below its high, after an 11% drop over the previous 30 trading days
52-week range $67.07 (Apr 8, 2025) to $86.94 (Dec 29, 2025), 47% of the way up, from 251 adjusted closes. 30 trading days earlier: $86.20 on Dec 30, 2025. Describes the past only, not a forecast
RSI 34, 4% under its 200-day average, 8% under its 50-day average, 12% below the 52-week high, 20-day volatility 27% a year, against the S&P 500: −7 points over 1 month, −10 points over 3 months, −7 points over 6 months
From the adjusted closes up to Feb 12, 2026. RSI: Wilder's 14-day relative strength index (0 to 100). Averages: the last 50 and 200 closes. Volatility: standard deviation of the last 20 daily returns, annualised. S&P 500: the stock's move minus SPY's between the same dates (21, 63 and 126 trading days). Describes the past only, not a forecast
None found in footnotes
Only flagged when a footnote says so; never inferred
A securities lawsuit naming the company as a defendant was filed on Oct 14, 2024 in the U.S. District Court, C.D. California. A filing is an allegation, not a finding.
Dhimant Patel v. Edwards Lifesciences Corporation, docket 8:24-cv-02221, via CourtListener (court records). Nature of suit 850, company named as first defendant
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | +5.0% | +0.7% | +4.4% |
| 30 days | +5.1% | −3.4% | +8.5% |
| 90 days | +5.0% | +8.2% | −3.1% |
| 180 days | +15.8% | +13.2% | +2.6% |
Past results only. Not a forecast.
Insider filing
Traded Mar 11 · filed the same day
Derivative exercise or conversion — not an open-market buy.
Scott B. Ullem (CVP, Chief Financial Officer) sold ~$431K of Edwards Lifesciences
Planned saleScott B. Ullem (CVP, Chief Financial Officer) sold ~$673K of Edwards Lifesciences
Planned saleEvery dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.